Related Experiment Video

Updated: Sep 30, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Recombinant erythropoietin in pediatrics: a clinical perspective

K M Shannon1

  • 1Department of Pediatrics, Naval Hospital, Oakland, CA 94627.

Pediatric Annals
|March 1, 1990
PubMed

Insights

Recombinant human erythropoietin (r-HuEPO) offers a promising alternative to blood transfusions for pediatric anemias, particularly in chronic renal failure and potentially in premature infants, reducing transfusion needs.

Area of Science:

  • Pediatric Hematology
  • Neonatology
  • Pharmacology

Background:

  • Red blood cell transfusions are common for pediatric anemias, especially in neonatal intensive care units.
  • Anemia in premature infants and chronic renal failure are significant concerns in pediatric care.
  • Recombinant human erythropoietin (r-HuEPO) is being investigated for its therapeutic potential.

Purpose of the Study:

  • To explore the efficacy of r-HuEPO as an alternative to blood transfusions in various pediatric anemia conditions.
  • To assess the potential of r-HuEPO in reducing transfusion requirements in neonatal intensive care units.
  • To investigate novel applications of r-HuEPO in pediatric hematological disorders.

Main Methods:

  • Review of current therapeutic strategies for pediatric anemias.
  • Analysis of existing data on r-HuEPO effectiveness in chronic renal failure.
  • Emphasis on the need for placebo-controlled trials for anemia of prematurity.

Main Results:

  • r-HuEPO is effective in correcting anemia associated with chronic renal failure in children.
  • r-HuEPO shows potential for significantly reducing blood transfusions in premature infants.
  • Further research is needed to establish its role in anemia of prematurity and other conditions.

Conclusions:

  • r-HuEPO presents a viable alternative to blood transfusions for several pediatric anemias.
  • Clinical trials are essential to confirm the benefits of r-HuEPO in neonatal anemia and other pediatric hematological conditions.
  • Future applications may include pre-surgical blood management and treatment of genetic blood disorders.

More Related Videos

Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors11:46

Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors

Published on: December 14, 2018

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo08:53

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Related Concept Videos

Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...